The Latest Breaking News from Novo Nordisk

GLP-1 drugs were initially developed for diabetes, but have become wildly popular weight-loss drugs too

It is ‘too early’ to know whether small doses of weight-loss drugs can help you live longer, experts say

Novo Nordisk A/S (NYSE:NVO) on Sunday presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025.

As GLP-1 use spreads, grocers and restaurants see lighter baskets, airlines predict fuel savings and health systems eye lower costs—while Denmark sees a clipped GDP.

As the demand for affordable healthcare options grows, the pharmaceutical industry is increasingly focused on developing generic drugs to expand access and reduce costs. This trend is driving major players to seek FDA approvals for generic versions of popular medications, reshaping the competitive landscape and providing more choices for consumers.

The FDA signed off on the first-ever weight-loss generic on Thursday, a knockoff of Novo Nordisk's Saxenda from Teva Pharmaceutical.

A panel convened in July 2025 by the Food and Drug Administration sparked controversy by casting doubt about the safety of commonly used antidepressants during pregnancy. But it also raised the broader issue of how little is known about the safety of many medications used in pregnancy, considering the implications…

Novo Nordisk stock remains under pressure this year. But the company is now launching Wegovy in MASH treatment. Can it make a comeback?

The U.S. Food and Drug Administration (FDA) has identified repeated quality control failures, including foreign particle contamination, inadequate investigations, and insufficient corrective actions at the Novo Nordisk A/S (NYSE:NVO) operated facility in Bloomington, Indiana.

Hims Hers Health Inc (NYSE:HIMS) investors can’t catch a break. Less than two months since Novo Nordisk AS (NYSE:NVO) terminated its Wegovy partnership with the telehealth company abruptly, the pharma giant is again in the news, this time partnering with GoodRx Holdings Inc (NASDAQ:GDRX) to provide discounted access to Ozempic…

Limit exposure to your employer's stock, sell it periodically and maintain portfolio diversification to protect your wealth from unexpected events.